Eko Health

Eko Health

Digital stethoscopes and AI diagnostic platform

Overview

Eko Health makes digital stethoscopes and a connected software platform to help detect and monitor heart and lung diseases. Its CORE 500 digital stethoscope digitizes sounds, boosts audio, cancels noise, and can visualize and record heart and lung sounds, while SENSORA analyzes those sounds with FDA-cleared AI to spot atrial fibrillation, heart murmurs, and low ejection fraction, with users accessing features through device hardware and subscriptions like Eko+. Revenue comes from device sales and SaaS plans. The company differentiates itself by tightly integrating AI analysis with connected stethoscope hardware, working with institutions like the Mayo Clinic, and focusing on primary care and telehealth at scale. Its goal is to improve early cardiovascular disease detection and patient outcomes by making advanced auscultation and AI analysis practical in daily clinical practice worldwide.

About Eko Health

Simplify's Rating
Why Eko Health is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

201-500

Company Stage

Series D

Total Funding

$234.2M

Headquarters

Oakland, California

Founded

2013

Get referred to Eko Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dr. Steven Steinhubl joined as CMO in May 2026, strengthening clinical credibility.
  • Wayne General Hospital deployment expands Eko into rural Mississippi care pathways.
  • International launches in the U.K. and Canada broaden revenue beyond U.S. hospitals.

What critics are saying

  • Eko still depends on clinicians adopting new workflows, despite reimbursement and evidence.
  • A June 2026 Bentonville layoff signaled operational strain and possible manufacturing cutbacks.
  • If SENSORA stalls after reimbursement, Eko becomes a hardware vendor with weak defensibility.

What makes Eko Health unique

  • Eko Health’s SENSORA gained CMS OPPS payment in December 2025, validating reimbursement.
  • The Lancet TRICORDER study showed 2.3x heart-failure, 3.5x AFib detection gains.
  • Boehringer Ingelheim partnership brought Eko Vet+ CANINEBEAT AI into U.S., U.K., Germany.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$234.2M

Below

Industry Average

Funded Over

10 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Below Average

Industry standards

$77M
$41M
Eko Health
$50M
Hello Fresh
$70M
Twilio
$80M
Handshake
$100M
Affirm

Benefits

Paid-time off

Medical/Dental/Vision, Disability + Life Insurance

Volunteer time off

One Medical membership

Parental Leave

401(k) Matching

Work from home equipment stipend

Flexible schedules

Wellness programs (Wellness Wednesdays, Time off)

Wellness perks (Headspace, Ginger, Aaptiv, Physera)

Learning and Development stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Investors Hangout
Jul 29th, 2026
AI cardiac diagnostics to skyrocket in 2036.

AI cardiac diagnostics to skyrocket in 2036. Investing in healthcare's next frontier. Well, if you've been keeping an eye on where healthcare's dollars are heading, take note: AI-driven cardiac diagnostics is taking the lead, and it's set to make some noise in the investment circles. Investors Hangout, LLC is talking a jump from USD 903.2 million in 2026 to a staggering USD 2,805.1 million by 2036. That's a 12.0% CAGR, and it's not just smoke - it's the real deal driven by numbers and need. Why AI in cardiac diagnostics? Let's break it down. Investors Hangout, LLC is seeing hospitals and clinics going all-in on AI because heart disease isn't slowing down, folks. It's on a bull run, and traditional methods just aren't cutting the mustard anymore. Artificial intelligence offers a way to speed up the process - think faster ECG interpretations and smarter imaging analysis. The tech isn't just flashy; it improves outcomes and prioritizes cases that matter. Healthcare systems are feeling the pressure, big time. More heart patients, not enough specialists, and complex monitoring needs make AI an attractive proposition. It's not just about saving time; it's about saving lives. Key players and competitive edge. So, who's neck-deep in this AI revolution? Heavyweights like GE HealthCare, Philips, and upstarts like Eko Health and AliveCor are in the race. It's all about who delivers high-performance algorithms and can achieve clinical validation. Not an easy game, but one worth watching if you're the investing type. "Companies that combine validated algorithms with scalable deployment models will better position themselves for long-term growth." - Anurag Sharma, Principal Analyst at Future Market Insights Leading segments: who benefits most? * Technology: Machine learning is owning 30.5% of the market. It's the magic sauce that analyzes ECG data and improves prediction accuracy - a hot ticket in the cardiology world. * Applications: Arrhythmia Detection is leading the charge with 31.4% market share. Given the massive amount of ECG data from various sources - hospitals, outpatient centers, remote monitoring - AI tools for identifying irregularities are crucial. * End Users: Hospitals are not just observers in this space. They hold a solid 33.5% market share. Their resources make them prime adopters of AI platforms to boost workflow and sync departments like cardiology, radiology, and ER. Tech deployment: cloud dominates. Then there's the cloud, holding a whopping 64.0% of market designs from 2026. It's about scalability and ease of management. But don't get complacent; there's more complexity beneath the surface. Providers want it secure, seamless, and reliable - or they're not buying. Geographic growth: south Korea in the spotlight. Let's talk geography, folks. South Korea is striding ahead with a 13.4% CAGR. With connected hospital networks and a big push toward digital healthcare, this country is not just filling counts - it's filling bank accounts. The USA's advanced infrastructure helps it ride closely with a 12.8% growth rate. As for Europe? Germany and the UK are stepping up thanks to digital overhauls, and Japan faces its aging population dilemma with innovation. Future Market Insights: shaping strategy. Looking to strategize your next move? Future Market Insights isn't just about numbers. Their research turns market complexity into opportunities, allowing leadership teams to identify growth opportunities faster while reducing uncertainties. To summarize. If you're contemplating where health tech is heading in the next decade, pay attention. AI-driven cardiac diagnostics is set to double in size as the healthcare world demands more speed, efficiency, and data-driven insights. Be it cloud solutions or smarter algorithms, those ready to tackle this frontier will find a market ripe for investment and innovation.

MPO Magazine
Jul 24th, 2026
Dr. Steven steinhubl joins Eko Health as chief medical officer.

Dr. Steven steinhubl joins Eko Health as chief medical officer. New hire will help advance clinical innovation and global impact of AI-enabled cardiac detection. July 24, 2026 Managing Editor Eko Health has appointed Steven R. Steinhubl, M.D., as chief medical officer (CMO) and member of the executive leadership team. In his new role, Dr. Steinhubl will help drive Eko's clinical strategy, research initiatives, and external scientific collaborations, further strengthening the evidence base and accelerating artificial intelligence (AI) adoption across health systems worldwide. His multidisciplinary background spanning engineering, physiology, and medicine positions him to bridge technology innovation with practical clinical application, executives claim. "Steve understands both the clinical realities of cardiovascular care and the promise of new technologies to improve it," Eko Health Co-Founder/CEO Connor Landgraf stated. "As Eko expands the global reach of AI-powered cardiac detection, his leadership will help ensure our work continues to translate into meaningful outcomes for clinicians and the patients they serve." Dr. Steinhubl is currently the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University in the Weldon School of Biomedical Engineering and is a member of the Regenstrief Center for Healthcare Engineering in West Lafayette, Ind. A globally recognized cardiologist, clinical researcher, and digital medicine pioneer, Dr. Steinhubl has dedicated his career to advancing cardiovascular care through the integration of wearable technologies, AI, and virtual-first care models. Dr. Steinhubl's research focuses on personal wearable sensor technologies, artificial intelligence and machine learning in healthcare, precision communication strategies in digital health, virtual-first care delivery, and the use of digital technologies to address health inequities. Over the course of his career, he has authored peer-reviewed publications and led large-scale clinical research initiatives aimed at improving early detection and prevention of cardiovascular disease. "As a clinician and researcher, I've long believed that the future of cardiovascular care lies in combining high-fidelity physiological data with intelligent analytics delivered seamlessly at the point of care," Dr. Steinhubl said. "Eko's platform represents a powerful step toward that future. By embedding AI into a tool clinicians already use every day, we can support earlier recognition of cardiac risk without disrupting workflow. I'm excited to help expand the scientific foundation, clinical partnerships, and real-world impact of this technology." Dr. Steinhubl's appointment arrives amid accelerating clinical and commercial momentum for Eko Health. Over the past year: * CMS finalized national payment for Eko Health's SENSORA platform under the Outpatient Prospective Payment System (OPPS). * Former U.S. Surgeon General Dr. Jerome Adams joined Eko Health as Distinguished Medical Advisor * The company reported results from the independently run landmark TRICORDER study published in The Lancet. Eko Health expanded deployment of its platform through new health system partnerships, including a recent rollout at Wayne General Hospital aimed at improving access to earlier cardiovascular screening in rural communities. Internationally, Eko Health launched its AI-powered stethoscope platform in the United Kingdom and expanded into Canada following Health Canada clearance of the CORE 500 Digital Stethoscope. Together, these milestones reflect growing global adoption of AI-assisted auscultation technologies designed to bring advanced cardiac detection into everyday clinical practice, the company claims. Eko Health is a pioneering AI early disease detection company advancing the way healthcare professionals detect and monitor heart and lung disease with its digital stethoscopes, ECG devices, software, and AI-powered analysis. Its U.S. Food and Drug Administration-cleared platform, with more than 700,000 devices sold worldwide, helps clinicians detect earlier and manage treatment more effectively to improve patient outcomes. Eko Health is headquartered in Emeryville, Calif.

PR Newswire
May 7th, 2026
Eko Health names Dr Steven Steinhubl as chief medical officer to advance AI cardiac detection

Eko Health has appointed Dr Steven Steinhubl as Chief Medical Officer. The cardiologist and digital health leader will drive clinical strategy, research initiatives and scientific collaborations to strengthen the evidence base for AI-enabled cardiac detection across health systems worldwide. Dr Steinhubl is currently the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University. His research focuses on wearable sensor technologies, artificial intelligence in healthcare and virtual-first care delivery. The appointment follows significant momentum for Eko Health, including CMS finalising national payment for its SENSORA platform, publication of the TRICORDER study in The Lancet, and international expansion into the UK and Canada. The company has sold over 700,000 devices worldwide.

Boehringer Ingelheim
Apr 27th, 2026
Boehringer Ingelheim and Eko Health inc. launch new AI-based solution that detects heart murmurs in dogs.

Boehringer Ingelheim and Eko Health inc. launch new AI-based solution that detects heart murmurs in dogs. Ingelheim, Germany and San Francisco, US, Wed, 29/04/2026 - 12:00 * Eko Vet+(TM) | CANINEBEAT(R) AI helps veterinarians detect, visualize, and grade heart murmurs in dogs that can otherwise go undetected * The CANINEBEAT(R) AI algorithm detects heart murmurs associated with structural heart disease in dogs with more than 95% sensitivity and specificity* * With earlier murmur detection, dogs can benefit from heart disease diagnostics and treatment sooner Boehringer Ingelheim, a global leader in animal health, and Eko Health, a leader in AI-powered cardiac and pulmonary disease detection, announced the launch of an innovative solution to detect, visualize, and grade heart murmurs in dogs. Eko Vet+(TM) | CANINEBEAT(R) AI aims to improve health outcomes for dogs with heart disease by enabling veterinarians to identify heart murmurs that might otherwise go unnoticed. "Our proprietary CANINEBEAT(R) AI algorithm integrated into the Eko Vet+(TM) app will powerfully support veterinarians' early detection of heart murmurs in dogs and pet owner conversations," said Dr. Erich Schött, Head of the Pet Business at Boehringer Ingelheim. "Heart murmur detection in dogs can be quite difficult, especially in busy clinics. Because pet owners don't see clinical signs in the early stage of heart disease, it's a challenge for veterinarians to explain that the dog suffers from a serious disease. With this unique AI solution, we can help detect murmurs earlier in the disease process, so dogs may receive appropriate diagnosis and treatment sooner." The new digital solution includes three integrated components: * The Eko CORE(TM) Digital Attachment connects to most single-tube stethoscopes and digitizes heart sounds that can then be analyzed by AI-based algorithms. It also helps veterinarians hear more subtle murmurs by amplifying heart sounds by 40 times and offers advanced noise cancellation and cardiac sound filtering. Other Eko devices also are compatible with the veterinary digital solution. * The CANINEBEAT(R) AI algorithm, trained and validated on more than 4,000 annotated canine heart sound recordings, detects heart murmurs associated with structural heart disease in dogs with more than 95% sensitivity and specificity.* The algorithm is intended to support veterinary clinical assessment and does not replace comprehensive cardiac evaluation or professional veterinary judgment. * The EkoVet+(TM) app incorporates insights from the CANINEBEAT(R) AI algorithm, including murmur images, sound files, and shareable reports. The app provides clinical support and helps veterinarians discuss the potential findings and any diagnostics and treatment needs with pet owners. Heart disease affects approximately 10% of all dogs.[1] The most common heart disease in dogs is myxomatous mitral valve disease (MMVD), which often produces a heart murmur when the heart has a leak in one of the heart valves, preventing blood from getting pumped correctly. MMVD is a chronic condition that is a major cause of morbidity and mortality in dogs.[2] Because dogs in early stages of heart disease may be asymptomatic, heart murmurs can go unnoticed during routine examinations. To address this challenge, 50 global veterinary cardiology experts contributed to the development of Eko Vet+TM with CANINEBEAT(R) AI. "CANINEBEAT(R) AI inside Eko Vet+(TM) is an exceptional resource for general practitioner veterinarians, helping them quickly detect and grade murmurs with a high level of consistency," said Prof. Gerhard Wess, Head of the Cardiology Service, Clinic for Small Animal Internal Medicine, Ludwig-Maximilians-Universität in Munich. "I am thrilled to be involved in the development of this new AI-powered solution that will give veterinarians greater confidence in heart murmur detection and support better outcomes for dogs." The introduction of this innovative auscultation solution for the veterinary industry has begun in the United States and the United Kingdom and will start in Germany next month. A phased expansion is planned in additional markets later this year and next. It will be available through both Boehringer Ingelheim and Eko Health, comprising the same three components through distinct commercial offers. "We've seen firsthand in human health how earlier, more accurate detection of cardiac disease can change the trajectory of care," said Connor Landgraf, CEO and co-founder of Eko Health. "Collaborating with Boehringer Ingelheim, a leader in canine cardiology, allows us to bring that same innovative approach to veterinary medicine. Together, we're equipping veterinarians with AI-powered tools to identify heart murmurs earlier and support better outcomes in canine patients." About Boehringer Ingelheim - Animal Health business. Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health. About Boehringer Ingelheim. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Its approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. About Eko Health. Eko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, ECG devices, software, and AI-powered analysis. Its FDA-cleared platform, with more than 700,000 devices sold worldwide, helps clinicians detect earlier and manage treatment more effectively to improve patient outcomes. Eko Health is headquartered in Emeryville, California. For more information, visit www.ekohealth.com. Media contacts. Mi-Kyung Lee Lange [email protected] Sam Moore [email protected] Editorial note. * The CANINEBEAT study was conducted using one of the largest canine digital auscultation datasets to date, comprising more than 4,000 heart sound recordings collected from over 3,400 dogs. The study assessed the performance of the CANINEBEAT(R) AI algorithm in detecting canine heart murmurs. All recordings were systematically annotated, with the algorithm's development and validation supported by nearly 50 veterinary cardiology experts. Detailed study results will be presented and published in peer reviewed scientific forums. References. [1] Keene, Bruce W et al. "ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs." Journal of veterinary internal medicine vol. 33,3 (2019): 1127-1140. https://doi.org/10.1111/jvim.15488 [2] Häggström, J et al. "New insights into degenerative mitral valve disease in dogs." Veterinary Clinics of North America: Small Animal Practice. 2004 vol 34, 5: 1209-1226. doi: 10.1016/J.CVSM.2004.05.002. Mi-Kyung Lee-Lange Animal Health Communications Lead

Built In
Apr 15th, 2026
Top healthcare companies and healthtech startups in Los Angeles.

Top healthcare companies and healthtech startups in Los Angeles. Pictor Labs uses artificial intelligence to process tissue samples. Its platform virtually stains these samples instead of using chemical stains, which enables clinicians to process biopsies much faster and without damaging the sample. Pictor Labs is based in LA and spun out of the UCLA Colleges of Engineering and Medicine in 2019. Eko Health is reimagining traditional medical devices by developing new hardware with high-tech capabilities. For example, its stethoscopes provide noise cancellation, digital amplification and ECG capabilities, enabling its clinicians to detect murmurs and other respiratory signs more easily. Eko Health also develops a telehealth platform designed for cardiac and pulmonary care by providing real-time streaming of heart and lung sounds. Regard develops an AI platform that works with Electronic Health Records (EHRs) software to manage patient data. The platform can automatically review a patient's medical history and to suggest care plans and can draft clinical notes for physicians. Regard is headquartered in New York, but also operates in LA. Flossy's software is focused on modernizing the patient experience, providing solutions for appointment booking and payment collection primarily. But, as of late Flossy has expanded into AI-driven tools that can help dental practices use AI agents to handle inbound calls and provide chatbot assistance to patients. Management consultancy ZS makes a cloud-based platform for healthcare business management. The platform, ZAIDYN, handles sales performance, analytics and reporting, and is used by over 100,000 pharma reps globally. The company also offers health plan consulting with the aim of increasing member acquisition and retention alongside commercialization strategy for rare disease therapies. TigerConnect delivers healthcare communications solutions to providers and other medical professionals designed to enhance staff productivity and improve relationships and outcomes with patients. The company offers a powerful suite of HIPAA compliant technologies and products including text and video messaging, workflow automation tools, analytics and other administrative integrations. TigerConnect's solutions streamline necessary operations to help hospitals and other medical facilities become more efficient and profitable. Artera provides digital solutions for the healthcare industry. For example, its consolidated communication platform facilitates patient outreach. Artera also introduced AI agents capable of handling routine tasks like billing inquiries, appointment scheduling and intake forms. Artera works with over 900 medical providers and is headquartered in Santa Barbara, California. GoodRx empowers consumers who are trying to get the best deals on prescription drugs. Its website and mobile app provide pricing options for more than thousands of medications, with real-time updates on discounts, coupons and price fluctuations. Beyond standard prescriptions and medication, GoodRx also provides discounts for common pet medications and offers telehealth services for various medical conditions. SimplePractice is a Santa Monica-based software company that makes it easier for medical professionals to take in new clients, converse with them, schedule future appointments and manage payments. Medical professionals from psychologists to social workers utilize SimplePractice's software tools, such as its automated note taker and telehealth platform, to grow their practices and run them more efficiently. Chorus Innovations is a digital healthcare platform that helps the healthcare industry create digital health solutions. The Chorus Innovations platform helps healthcare providers, with no coding and programming knowledge, create visually-appealing and highly-functional apps. Healthcare providers can create surveys and patient portals, and can integrate SMS and voice in their apps with the no-code platform. Ritual is a direct-to-consumer multivitamin brand. Ritual's vitamins contain traceable nutrients, non-GMOs, no artificial colorants and are vegan friendly. The company has vitamins specifically made for men, women and children, including both pre and post-natal vitamins for mothers. Medely is an on-demand platform for healthcare professionals to find per diem work. Health professionals, like Registered Nurses and Techs, use Medely to book short-term and per diem work at local healthcare facilities. These professionals set their own schedules, see daily job opportunities and can accept jobs that fit their skill level. Nigagen is an integrated nutraceutical company dedicated to improving the way people age. The company's team of scientists partner with universities and research institutions to identify and develop novel, science-based ingredients. Its flagship product, NIAGEN, increases nicotinamide adenine dinucleotide (NAD) - a vital resource that can aid in energy production and counteract cellular aging. Santa Monica based, Headspace is a mobile platform promoting mental health through meditation sessions and training in mindfulness. In addition to their southern California headquarters, Headspace has locations in San Francisco and London and is used by millions of users across 190 countries. DivvyDOSE is an online pharmacy delivering individualized packs of medications to patients. DivvyDOSE makes it easier for patients to order and take their prescription medication. All patients have to do is sign up, transfer their prescription and the company will build and deliver them straight to the patient's door. The prescriptions come in individual packets with the date, time and contents listed clearly on each package. Anagram enables healthcare providers to allow patients to use their healthcare benefits and claims regardless of their insurance networks. The company aims to make paying for healthcare and leveraging insurance benefits a simple and transparent experience for both providers and patients. Medversant pulls together numerous files and databases into one hub, helping medical providers follow compliance regulation and reduce administrative burden. Its other tools can also help with Medicaid enrollments and facilitating peer review processes. Medversant was founded in 1999 and is headquartered in Los Angeles. NantHealth is a healthcare IT company providing solutions for medical providers and hospitals. Its flagship products, NaviNet and Eviti, help streamline financial and clinical data, assisting both patients and providers to ensure bills and treatments are accurate. NantHealth is headquartered in North Carolina but operates a location in El Segundo, California. With an eye toward transparency, Push Health uses technology to bring together patients and providers in a tight network. Its platform can connect patients with licensed healthcare providers for telehealth consultations, lab tests and prescription refills thanks to a partnership with Quest Diagnostics. Founded in 2012, Push Health is headquartered in El Segundo, California. With a mission to "bring clarity to healthcare decisions," WiserCare is an information clearinghouse and support system for patients and providers alike. By cutting through medical jargon and helping consumers and medical professionals communicate clearly, WiserCare helps people get more effective treatment and navigate scary terrain with more confidence. LA-based 1-800-DENTIST connects consumers with local pre-screened dental professionals based on their specific needs. The company launched in 1986as a call-in service but has since expanded to a digital platform connecting millions of individuals to qualified dentists. Axle Health aims to empower home health care providers. It builds scheduling and workforce management solutions like automated patient engagement, route optimization and AI scheduling. The company has an office in Santa Monica near Palisades Park.

Recently Posted Jobs

Sign up to get curated job recommendations

Eko Health is Hiring for 6 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →